Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedMinor platform version update reflected in the Record History page: Revision v3.3.4 added and Revision v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedRevision: v3.3.3 appears on the page, and 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' are removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page history now lists Revision: v3.3.2, replacing v3.2.0. This appears to be a routine system release update rather than a change to study content or user-facing functionality.SummaryDifference0.1%

- Check66 days agoChange DetectedThe notice about government funding and potential delays was removed from the page. This banner previously informed users about data reliability and operating status.SummaryDifference0.4%

- Check80 days agoChange DetectedThe Record History page now shows additional recent versions with updated submission dates and status notes. The version history appears longer, reflecting ongoing updates to the study record.SummaryDifference0.1%

- Check102 days agoChange DetectedAdds current date (2025-10-10) and a new study status entry (2025-09-30), while removing an older date (2025-06-13. Overall, updates to time-sensitive content and status tracking.SummaryDifference0.8%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.